Hansa Biopharma AB (publ)
Other OTCCapital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.- CEO
- Renee Aguiar-Lucander
- Full Time Employees
- 138
- Sector
- Healthcare
- Industry
- Biotechnology
- Address
- PO Box 785 Lund Sweden 220 07
- IPO Date
- Mar 25, 2015
- Website
- hansabiopharma.com
- Similar Companies
- Business
- Hansa Biopharma AB (publ) (Nasdaq Stockholm: HNSA) operates as a commercial-stage biopharmaceutical company that develops and commercializes innovative immunomodulatory enzyme therapies targeting pathogenic IgG antibodies for patients with rare immunological conditions, including transplant rejection, highly sensitized kidney transplantation, IgG-mediated autoimmune diseases, and gene therapy pretreatment; its proprietary antibody-cleaving enzyme technology platform features lead product Imlifidase (marketed as IDEFIRIX in Europe), a first-generation enzyme for rapid single-dose IgG inactivation, and next-generation candidate HNSA-5487 for potential repeat dosing. Founded in 2007 and headquartered in Lund, Sweden, the company maintains operations across Europe and the US, serving transplant centers, clinicians treating acute immune disorders, and gene therapy developers. In October 2025, Hansa completed a directed share issue raising approximately SEK 671 million to support clinical programs and extend cash runway into Q2 2026; earlier in 2025, it secured additional financing and restructured debt with NovaQuest. Recent clinical advancements include imlifidase meeting its primary endpoint in the US Phase 3 ConfIdeS trial for kidney transplantation in October 2025, positive Phase 1b data supporting its use to reduce anti-AAV antibodies for gene therapy access, and October 2025 results from the GNT-018-IDES trial confirming feasibility as pretreatment for Crigler-Najjar syndrome gene therapy. Partnerships encompass commercialization deals such as with NewBridge Pharmaceuticals for IDEFIRIX supply in the Middle East and North Africa, alongside ongoing collaborations in drug discovery, development, and distribution.
Hansa Biopharma AB (publ) (HNSBF) Discusses Top Line Results from PAES Study on Imlifidase in Highly Sensitized Kidney Transplant Patients Transcript
Hansa Biopharma reports positive efficacy and safety results from Idefirix® European post authorization study in kidney transplantation
Hansa Biopharma Announces Late-Breaking Abstract from ConfIdeS Phase 3 Trial Selected for Oral Presentation at ATC 2026
Hansa Biopharma AB (publ) (HNSBF) Discusses Out-Licensing Agreement With SERB for Idefirix Commercialization in Europe and MENA Transcript
Hansa Biopharma enters into €115 million licensing agreement with SERB Pharmaceuticals for IDEFIRIX in Europe and MENA
SERB Pharmaceuticals to acquire European and MENA rights to Idefirix® (imlifidase) from Hansa Biopharma for €115 million
Hansa Biopharma AB (publ) (HNSBF) Q1 2026 Earnings Call Transcript
Hansa Biopharma AB (publ) (OTCMKTS:HNSBF) Short Interest Down 15.6% in March
Hansa Biopharma AB (publ) (HNSBF) Q4 2025 Earnings Call Transcript
Hansa Biopharma has won the 2025 SwedenBIO Award
Hansa Biopharma AB (publ) (HNSBF) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript
Hansa Biopharma AB (publ) (HNSBF) Discusses Phase III Trial Data and Developments in IgG-Cleaving Platform for Kidney Transplantation and Autoimmune Diseases Transcript
Hansa Biopharma AB (publ) (HNSBF) Q3 2025 Earnings Call Transcript
Hansa hosts call with distinguished transplant surgeons: Insights on clinical practice and imlifidase Phase 3 Results
Hansa Biopharma AB (publ) - Special Call
Hansa Biopharma AB (publ) (HNSBF) Q2 2025 Earnings Call Transcript
Hansa Biopharma AB (publ) (HNSBF) Q1 2025 Earnings Call Transcript
Hansa Biopharma AB (HNSBF) Q4 2024 Earnings Call Transcript
Hansa Biopharma announces positive full results from 15-HMedIdeS-09 Phase 2 study and comparative analysis of imlifidase in patients with Guillain-Barré Syndrome
Genethon and Hansa Biopharma Announce Initiation of a Phase 2 Trial of imlifidase as a Pre-Treatment to GNT-0003 in Severe Crigler-Najjar Syndrome